Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H J Bloemendal

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
The Netherlands Journal of Medicine|July 1, 1996
Hyperamylasaemia in multiple myelomaH J Bloemendal, S Lobatto
European Journal of Clinical Investigation|September 1, 1999
New strategies in anti-vascular cancer therapyH J Bloemendal, T Logtenberg, E E Voest
Nederlands Tijdschrift Voor Geneeskunde|April 2, 2003
[Cerebral infarction and myocardial infarction due to cisplatin-containing chemotherapy]M E E Brouha, H J Bloemendal, L J Kappelle, et al.
British Journal of Cancer|April 12, 2017
Towards better dose individualisation: metabolic phenotyping to predict cabazitaxel pharmacokinetics in men with prostate cancerA Janssen, C P M Verkleij, A van der Vlist, et al.
Nuclear Medicine and Biology|February 10, 2015
Drug composition matters: the influence of carrier concentration on the radiochemical purity, hydroxyapatite affinity and in-vivo bone accumulation of the therapeutic radiopharmaceutical 188Rhenium-HEDPR Lange, J M H de Klerk, H J Bloemendal, et al.
European Journal of Cancer (Oxford, England : 1990)|July 20, 2020
Impact of the coronavirus disease 2019 pandemic on cancer treatment: the patients' perspectiveK de Joode, D W Dumoulin, V Engelen, et al.
The Netherlands Journal of Medicine|September 30, 2010
Lapatinib: clinical benefit in patients with HER 2-positive advanced breast cancerJ R Kroep, S C Linn, E Boven, et al.
BMC Cancer|April 21, 2017
Imatinib treatment of poor prognosis mesenchymal-type primary colon cancer: a proof-of-concept study in the preoperative window period (ImPACCT)I Ubink, H J Bloemendal, S G Elias, et al.
ESMO Open|April 22, 2021
Prospective experimental treatment of colorectal cancer patients based on organoid drug responsesS N Ooft, F Weeber, L Schipper, et al.
Acta Oncologica (Stockholm, Sweden)|July 21, 2017
Nationwide comprehensive gastro-intestinal cancer cohorts: the 3P initiativeR R J Coebergh van den Braak, L B van Rijssen, J J van Kleef, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
The Netherlands Journal of Medicine|July 1, 1996
Hyperamylasaemia in multiple myelomaH J Bloemendal, S Lobatto
European Journal of Clinical Investigation|September 1, 1999
New strategies in anti-vascular cancer therapyH J Bloemendal, T Logtenberg, E E Voest
Nederlands Tijdschrift Voor Geneeskunde|April 2, 2003
[Cerebral infarction and myocardial infarction due to cisplatin-containing chemotherapy]M E E Brouha, H J Bloemendal, L J Kappelle, et al.
British Journal of Cancer|April 12, 2017
Towards better dose individualisation: metabolic phenotyping to predict cabazitaxel pharmacokinetics in men with prostate cancerA Janssen, C P M Verkleij, A van der Vlist, et al.
Nuclear Medicine and Biology|February 10, 2015
Drug composition matters: the influence of carrier concentration on the radiochemical purity, hydroxyapatite affinity and in-vivo bone accumulation of the therapeutic radiopharmaceutical 188Rhenium-HEDPR Lange, J M H de Klerk, H J Bloemendal, et al.
European Journal of Cancer (Oxford, England : 1990)|July 20, 2020
Impact of the coronavirus disease 2019 pandemic on cancer treatment: the patients' perspectiveK de Joode, D W Dumoulin, V Engelen, et al.
The Netherlands Journal of Medicine|September 30, 2010
Lapatinib: clinical benefit in patients with HER 2-positive advanced breast cancerJ R Kroep, S C Linn, E Boven, et al.
BMC Cancer|April 21, 2017
Imatinib treatment of poor prognosis mesenchymal-type primary colon cancer: a proof-of-concept study in the preoperative window period (ImPACCT)I Ubink, H J Bloemendal, S G Elias, et al.
ESMO Open|April 22, 2021
Prospective experimental treatment of colorectal cancer patients based on organoid drug responsesS N Ooft, F Weeber, L Schipper, et al.
Acta Oncologica (Stockholm, Sweden)|July 21, 2017
Nationwide comprehensive gastro-intestinal cancer cohorts: the 3P initiativeR R J Coebergh van den Braak, L B van Rijssen, J J van Kleef, et al.
Pageof 1